Literature DB >> 18035606

The mechanism of isoniazid killing: clarity through the scope of genetics.

Catherine Vilchèze1, William R Jacobs.   

Abstract

Isoniazid (INH) is one of the most efficient drugs for the treatment of Mycobacterium tuberculosis infections. Despite its rather simple chemical structure, the mechanism by which INH kills M. tuberculosis is complex. A full understanding of the mechanisms of action of INH required the development of genetic tools in M. tuberculosis. Herein, we discuss the different hypotheses that have been used to describe INH action against M. tuberculosis over the past 50 years in terms of the pregenetic and genetic era. We also review the different mechanisms of INH resistance and propose what we think is the means by which INH kills M. tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18035606     DOI： 10.1146/annurev.micro.61.111606.122346

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN： 0066-4227            Impact factor:   15.500


  115 in total

1.  Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.

Authors:  Benjamin Schaefer; Caroline Kisker; Christoph A Sotriffer
Journal:  J Comput Aided Mol Des       Date:  2011-11-11       Impact factor: 3.686

2.  Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.

Authors:  Claudio U Köser; Richard N Veerapen-Pierce; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2010-10       Impact factor: 5.191

3.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

4.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

5.  Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism.

Authors:  Yoann Rombouts; Belinda Brust; Anil K Ojha; Emmanuel Maes; Bernadette Coddeville; Elisabeth Elass-Rochard; Laurent Kremer; Yann Guerardel
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

6.  The 52nd Annual Wind River Conference On Prokaryotic Biology--2008.

Authors:  E Mann; M A Zaunbrecher; K Hitz; G Churchward
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

7.  A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria.

Authors:  Deborah Mai; Jennifer Jones; John W Rodgers; John L Hartman; Olaf Kutsch; Adrie J C Steyn
Journal:  Assay Drug Dev Technol       Date:  2011-01-31       Impact factor: 1.738

Review 8.  Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Authors:  Sumit Chakraborty; Kyu Y Rhee
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

9.  In vitro model of mycobacterial growth arrest using nitric oxide with limited air.

Authors:  Syed Hussain; Muhammad Malik; Lanbo Shi; Maria Laura Gennaro; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.

Authors:  Christine E Cade; Adrienne C Dlouhy; Katalin F Medzihradszky; Saida Patricia Salas-Castillo; Reza A Ghiladi
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.